uniQure (NASDAQ:QURE) Shares Up 9.1% – What’s Next?

uniQure N.V. (NASDAQ:QURE) shares rose 9.1% during trading on Monday . The stock traded as high as $18.80 and last traded at $19.1740. Approximately 841,828 shares traded hands during mid-day trading, a decline of 72% from the average daily volume of 3,014,750 shares. The stock had previously closed at $17.58.

Wall Street Analyst Weigh In

QURE has been the topic of several research reports. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $9.00 price objective (down from $55.00) on shares of uniQure in a research report on Monday, March 2nd. Wall Street Zen raised shares of uniQure from a “sell” rating to a “hold” rating in a research report on Saturday, March 28th. Wells Fargo & Company raised shares of uniQure from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $15.00 to $60.00 in a research report on Monday, March 9th. The Goldman Sachs Group boosted their price target on shares of uniQure from $9.00 to $10.00 and gave the stock a “neutral” rating in a research report on Monday. Finally, HC Wainwright reissued a “buy” rating and set a $70.00 price target on shares of uniQure in a research report on Tuesday, March 10th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, uniQure presently has a consensus rating of “Moderate Buy” and an average target price of $42.83.

uniQure Stock Up 3.0%

The firm’s 50-day simple moving average is $17.67 and its 200 day simple moving average is $28.10. The company has a debt-to-equity ratio of 0.25, a quick ratio of 10.43 and a current ratio of 10.43. The stock has a market capitalization of $1.13 billion, a P/E ratio of -5.27 and a beta of 0.75.

uniQure (NASDAQ:QURE) last issued its quarterly earnings results on Tuesday, March 3rd. The biotechnology company reported ($0.56) EPS for the quarter, topping the consensus estimate of ($0.93) by $0.37. uniQure had a negative net margin of 1,236.00% and a negative return on equity of 174.03%. The firm had revenue of $5.57 million for the quarter, compared to analysts’ expectations of $4.84 million. As a group, research analysts expect that uniQure N.V. will post -3.75 EPS for the current year.

Insiders Place Their Bets

In other news, insider Jeannette Potts sold 3,412 shares of the business’s stock in a transaction dated Wednesday, March 4th. The shares were sold at an average price of $9.06, for a total transaction of $30,912.72. Following the transaction, the insider directly owned 138,483 shares in the company, valued at $1,254,655.98. The trade was a 2.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Matthew C. Kapusta sold 14,581 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total transaction of $132,103.86. Following the transaction, the chief executive officer owned 660,658 shares in the company, valued at $5,985,561.48. This represents a 2.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 49,396 shares of company stock valued at $722,734 in the last three months. 4.79% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Private Trust Co. NA acquired a new position in shares of uniQure during the 3rd quarter worth about $28,000. Torren Management LLC acquired a new position in shares of uniQure during the 4th quarter worth about $28,000. Jones Financial Companies Lllp increased its stake in shares of uniQure by 509.0% during the 3rd quarter. Jones Financial Companies Lllp now owns 609 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 509 shares during the last quarter. IFP Advisors Inc acquired a new position in shares of uniQure during the 4th quarter worth about $48,000. Finally, Smartleaf Asset Management LLC acquired a new position in shares of uniQure during the 4th quarter worth about $48,000. 78.83% of the stock is currently owned by institutional investors and hedge funds.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.